Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
4.000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
1 Gene Editing Stock to Buy Now, and 1 to Sell
September 23, 2023
Target markets matter. So does having the cash to get to them.
Via
The Motley Fool
Analyst Expectations for Editas Medicine's Future
August 29, 2023
Via
Benzinga
Expert Ratings for Editas Medicine
August 03, 2023
Via
Benzinga
Is Editas Medicine Stock a Buy Now?
June 28, 2023
The fortunes of this once-promising biotech company have changed in the past year.
Via
The Motley Fool
What 6 Analyst Ratings Have To Say About Editas Medicine
June 13, 2023
Via
Benzinga
Editas Medicine's Return On Capital Employed Insights
May 19, 2023
Via
Benzinga
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
August 23, 2023
Is the Street's optimism justified here?
Via
The Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
June 29, 2023
Reaching profitability could be harder than investors expect.
Via
The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
June 25, 2023
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.
Via
Talk Markets
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
June 20, 2023
It's not about to start making money anytime soon.
Via
The Motley Fool
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 15, 2023
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
Via
Benzinga
6 Analysts Have This to Say About Editas Medicine
May 08, 2023
Via
Benzinga
Editas Medicine: Q1 Earnings Insights
May 05, 2023
Via
Benzinga
2 Short-Squeeze Candidates That Could Go Parabolic
June 15, 2023
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.
Via
The Motley Fool
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 15, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
June 13, 2023
Via
Benzinga
Preview: Editas Medicine's Earnings
May 04, 2023
Via
Benzinga
2 Stocks Under $15 Per Share to Consider
April 16, 2023
Anyone can get in on the stock market at these prices.
Via
The Motley Fool
5 Stocks to Buy With Explosive 500% Potential
June 12, 2023
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.
Via
InvestorPlace
Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
June 09, 2023
Editas Medicine Inc (NASDAQ: EDIT) annou
Via
Benzinga
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
June 06, 2023
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.
Via
InvestorPlace
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
June 01, 2023
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that...
Via
Benzinga
7 Short-Squeeze Stocks Set for a May Rally
May 22, 2023
While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns.
Via
InvestorPlace
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
May 21, 2023
It's facing a few issues that are practically guaranteed to affect shareholder returns.
Via
The Motley Fool
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 15, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Earnings Scheduled For May 5, 2023
May 05, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
Via
Benzinga
The 3 Most Promising Gene Editing Stocks to Buy in 2023
April 28, 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.
Via
InvestorPlace
Why Shares of Editas Medicine Rose Monday
April 17, 2023
The company is benefiting from positive news affecting other gene-editing stocks.
Via
The Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.